Company intelligence / Profile preview

PointLoma Biosciences

San Diego, California, USApmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

PointLoma Biosciences is developing off-the-shelf, allogeneic γδ T cell therapies engineered with dual chimeric antigen receptors (CARs) to target both tumor cells and the immunosuppressive stroma within the tumor microenvironment. The technology also incorporates gene editing strategies to overcome immune suppression in solid tumors. No clinical results have been published yet; programs are likely preclinical or at IND-enabling stages based on available information from scientific presentations in 2024–2025.

Therapeutic areas: Oncology
Modalities: Cell therapy (specifically allogeneic γδ T cell therapy)Gene editing (as part of their approach to enhance cell therapies)
Industry: Biotech

Beyond the preview

Go deeper on PointLoma Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PointLoma Biosciences.

Explore the full profile